In a study of patients with non-metastatic breast cancer or NHL receiving high or intermediate FN risk chemotherapy regimens, the incidence of FN in the first cycle was 4–9% in patients who received G-CSF prophylaxis [18]. This evidence concerns the gene CSF3 and breast cancer.